With the Food and Drug Administration (FDA)’s approval of Harvoni, the successor to Gilead Science’s Sovaldi, the alarm bells have officially rung on breakthrough hepatitis C treatments. One can’t open a newspaper or scan a Twitter feed without stumbling
Read More...
Read the complete post at http://healthaffairs.org/blog/2014/11/21/sovaldi-harvoni-and-why-its-different-this-time/
Posted
Nov 21 2014, 11:18 AM
by
Health Affairs Blog